



**Health Advance Inc.**

9131 Keele Street, Suite A4  
Vaughan, Ontario, Canada L4K 0G7

(705) 733-7098

[www.HealthAdvanceGroup.com](http://www.HealthAdvanceGroup.com)

[President@HealthAdvanceGroup.com](mailto:President@HealthAdvanceGroup.com)

SIC Code 5990 - Retail-Retail Stores – Other Specialty Retail

**Annual Report**

**For the Twelve Months Ending: March 31, 2022**  
(the "Reporting Period" Fiscal 2021)

As of the Current Reporting Period Date, March 31, 2022,  
the number of shares outstanding of our Common Stock was: 160,947,500

As of the Prior Reporting Period, the Quarter ending December 31, 2021,  
the number of shares outstanding of our Common Stock was: 160,947,500

As of the Most Recent Completed Fiscal Year ending March 31, 2021,  
the number of shares outstanding of our Common Stock was: 160,947,500

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐

No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐

No: ☒

Indicate by check mark whether a Change in Control<sup>1</sup> of the company has occurred over this reporting period:

Yes: ☐

No: ☒

---

(i) Any "person" (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;

**1) Name and address(es) of the issuer and its predecessors (if any)**

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

HEALTH ADVANCE INC

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

WYOMING, April 14, 2010, ACTIVE

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

NONE

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

NONE

The address(es) of the issuer's principal executive office:

9131 KEELE STREET, SUITE A4  
VAUGHAN, ONTARIO, L4K 0G7  
CANADA

The address(es) of the issuer's principal place of business:

*Check box if principal executive office and principal place of business are the same address:* ☒

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐ No: ☒

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

NOT APPLICABLE

---

(ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;

(iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or

(iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

## 2) Security Information

Trading symbol: **HADV**

Exact title and class of securities outstanding: **COMMON SHARES**

CUSIP: **42225L203**

Par or stated value: **.001**

Total shares authorized: **500,000,000** as of date: **MARCH 31, 2022**

Total shares outstanding: **160,947,500** as of date: **MARCH 31, 2022**

Number of shares in the Public Float<sup>2</sup>: **50,925,500** as of date: **MARCH 31, 2022**

Total number of shareholders of record: **70** as of date: **MARCH 31, 2022**

*All additional class(es) of publicly traded securities (if any):* **NOT APPLICABLE**

### Transfer Agent

Name: **AMERICAN STOCK TRANSFER (AST)**

Phone: **(800) 937-5449**

Email: **HELP@ASTFINANCIAL.COM**

Address: **2390 EAST CAMELBACK ROAD, SUITE 240  
PHOENIX, ARIZONA  
85016**

Is the Transfer Agent registered under the Exchange Act?<sup>3</sup> Yes: ☒ No: ☐

## 3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period**.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

### **A. Changes to the Number of Outstanding Shares**

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☐

---

<sup>2</sup> "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

<sup>3</sup> To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.



## B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe all outstanding promissory notes, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: ☐

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g. Loan, Services, etc.)
Mar 31/19	43,191.17 (The amount fluctuates, operating as a revolving line of credit).	2,500.00	Nil	Demand Loan	Repayable in Cash or Restricted Common Shares at \$0.05 Price	Fit For A King Inc, Gerry Pettie	Working Capital
May 25/21	20,697.33	20,697.33	Nil	May 25/22	Convertible at \$0.025	Sydney Bernstein	Working Capital
May 27/21	20,697.33	20,697.33	Nil	May 27/22	Convertible at \$0.025	Arthur Stemerman	Working Capital
Jun 02/21	20,697.33	20,697.33	Nil	Jun 02/22	Convertible at \$0.025	Luigi Buttino	Working Capital
July 07/21	20,697.33	20,697.33	Nil	Jul 07/22	Convertible at \$0.025	Ne'eman Foundation Canada Charm Katz	Working Capital
Oct 27/21	72,000.00	72,000.00	Nil	Oct 27/22	40%	J.P.Carey Limited Partnership/ Joe Canouse	Working Capital
Jan 27/22	57,000.00	57,000.00	Nil	Jan 27/23	40%	J.P.Carey Limited Partnership/ Joe Canouse	Working Capital

Use the space below to provide any additional details, including footnotes to the table above:

Fit For A King, Inc, provided working capital for the purpose of attaining OTC Markets current information designation, restoration of all other regulatory compliance and expansion of early business operations, in return for eventual repayment and future consideration to be determined.

## 4) Financial Statements

A. The following financial statements were prepared in accordance with:

- ☒ U.S. GAAP  
☐ IFRS

B. The financial statements for this reporting period were prepared by (name of individual)<sup>4</sup>:

Name: Internal

Title:

Relationship to Issuer:

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- C. Balance sheet;
- D. Statement of income;
- E. Statement of cash flows;
- F. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- G. Financial notes; and
- H. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report," "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below. Financial Statements must be compiled in one document.

#### FINANCIAL STATEMENTS INCLUDED HEREIN

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

#### 5) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

**RECAP OF CONTEXT** – The reader is encouraged to peruse preceding HADV OTC Markets filings for continuity.

Health Advance Inc is preparing to launch new proprietary CBD infused wine beverage products in the summer of 2022 and a new proprietary nutraceutical product range in 2023.

- B. Please list any subsidiaries, parents, or affiliated companies.

Subsidiary

50% ownership of [www.CourtshipWines.com](http://www.CourtshipWines.com)

Association

Winning Brands Corporation has a brand development consultancy relationship to be compensated with profit sharing according to terms that will correspond with the success of the contemplated ventures.

---

<sup>4</sup> The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS by persons with sufficient financial skills.


C. Describe the issuers' principal products or services.

#### **CBD INFUSED WINE BEVERAGES**

Health Advance has carried out consumer research to determine which approach to the commercialization of the Company's proprietary CBD wine beverages strikes the most efficient balance between commercial opportunity and regulatory constraints. In response to the findings of this research, New York State was selected for licensing. The Certificate of Licensure was issued, shown below, shortly after the end of the March 31, 2022 reporting period.



An additional finding of this research was a consensus amongst experts that exceptional growth of interest in non-alcoholic adult beverages in the food & beverage industry is occurring. This has been reiterated by mainstream media and business press reporting. CNN reporting provided herewith. VIDEO LINK: <https://www.youtube.com/watch?v=XhUM5saUGDI&t=1s>



For these reasons, and the likelihood of a roll-out with mainstream grocery partners of a de-alcoholized product initially, the following product characterizations have been adopted Health Advance's initial CBD product positioning. A wide range of marketing initiatives will be undertaken in the summer of 2022, and beyond, to support the launch of Health Advance's first product range in this category under the branding 66° Beverage Company.




## WELLNESS & PLEASURE PLUS

### CBD Beverages

Never before have so many people discovered and appreciated the benefit of legally extracted CBD oils for specific wellness benefits.

Health Advance has already applied for, and has been granted its New York State CBD beverage manufacturing license.



*Photo Caption: Unique de-alcoholized CBD infused wine gives the market a new twist as consumers embrace innovative non-alcoholic options in the adult beverage lifestyle. 66° Beverage Company from Health Advance Inc (OTC:HADV) is right on target for this sector for launch purposes.*




## NUTRACEUTICALS

Health Advance has a history of seeking the launch of a nutraceutical range. Previous attempts sought to acquire formulations developed by 3<sup>rd</sup> parties, either through purchase or licensing. Progress was hampered by operational details external to Health Advance. As a result, a new approach is being adopted instead, namely, to develop the product internally. In March 2022, Health Advance announced its intention to proceed with this initiative.

March 17 2022

### Assistance for Long COVID Sufferers Targeted by Health Advance, Inc



## Assistance for Long COVID Sufferers Targeted by Health Advance, Inc

Thursday, March 17, 2022 3:10 PM

Topic: **Company Update** Share this Article [in](#) [f](#) [t](#)

*Proprietary Techniques for a Burgeoning Problem*

**NEW YORK, NY / ACCESSWIRE / March 17, 2022 /** Health Advance, Inc (OTC PINK:HADV) [www.HealthAdvanceGroup.com](http://www.HealthAdvanceGroup.com) is launching a joint venture to supply new treatment options for the growing number of people internationally who are past their COVID illness, yet suffer from lingering generalized weakness and lack of well-being.

The joint venture, provisionally called Health Advance CV, will operate as a division of Health Advance Inc to provide affected persons with a curated nutraceutical regime for this condition through pre-packaged proprietary supplement pouches where regulations permit, utilizing infusion techniques and novel combinations to deliver superior results over conventional supplement methods. The new product name will be announced separately.

Leader of the Health Advance Science Team for the new venture is Dr. Alvin Pettie, a practicing anti-aging and bio-identical hormone specialist. Dr. Pettie is applying his medical philosophy to this launch derived from decades of clinical observation intended to protect consumers from casual experimentation with nutraceuticals without adequate understanding of the importance of proper combination. According to Dr. Pettie, a lost opportunity for optimal human immune system tuning arises from the abundance of choice confronting consumers within today's complex supplement options.

Dr. Pettie remarks, "It's impossible for consumers to casually know how to combine available supplements for maximum impact. Deep expertise in effective combinations and timing makes an immense difference. I have decades of life-giving medical experience. An over-arching observation by me in use of supplements by patients is that combination guidance is a key missing factor, not a lack of safe and effective supplements, per se. Our initiative is going to make it easy, safer and more effective for consumers through a systematic kit approach that will be prepared with exceptionally relevant specific knowledge. The kits will be made intuitive to normal daily life routines for effortless compliance by sufferers of this condition, and others. Doctors know that reliable patient compliance is a huge issue. Our design addresses this as the starting point, and then builds sophisticated pairings of elements. We are bringing fresh inspiration and modern concepts. Enormous interest in this project is already being shown by consumers eager to have insightful options in this category."

The current status of this project is active internal development of a nutraceutical sachet that has the following attractive market characteristics:

- *Ease of entry into the US market. (Still the largest supplement market in the world)*
- *Doctor Formulated*
- *Access to exclusive content from formulating practitioner including blogs, videos and video calls/chats*
- *Vegan / Plant Based / Vegetarian Friendly*
- *Nut Free / Gluten Free / Dairy Free*
- *Costs - The same as a "Latte per Day"*
- *Costs - It would cost consumers 3x more per month if they tried to buy ingredients separately*
- *Portable - Consumers can travel with the sachets conveniently. Gym bag, Purse, Luggage*
- *Freshness - pouch number 30 of monthly supply is just as fresh as the first*
- *Easy to Use, Intuitive*
- *Easy for consumers to choose a subscription service for automatic monthly orders*
- *With QR code, gaining access to consumers directly through smartphone daily reminders and monthly reminders if they are not on a subscription model. Messaging for exclusive content to members.*

Design development work for this product range is still ongoing. The initial approach is shown below:



## 6) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

Health Advance former management was, in the past, not local to the Company's official business address. Current management has rectified this situation, as shown below. Courtship Wines facilities will be reported upon activation of production and distribution, corresponding to use at that time.



*Health Advance occupies a modern shared-use office premises within reasonable proximity of management, consultants, and service providers.*



*The facility accommodates all foreseeable meeting and collaboration requirements at modest rent within industry norms.*

## 7) Company Insiders (Officers, Directors, and Control Persons)

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information, as of the period end date of this report, regarding any person or entity owning 5% of more of any class of the issuer's securities, as well as any officer, and any director of the company, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

**ADVISORY NOTE TO READER:** The holdings described below are presented by the Company without prejudice vis a vis any potential claim or off-set that may be made by the Company at any time in the future, either as Plaintiff or Defendant, or in any administrative proceeding with regard to vesting, completion of contract, earned entitlement or any other factor affecting beneficial ownership. This chart is not evidentiary. Domestic and International Clearing agencies, such as CEDE for illustration, are not included as beneficial owners.

Name of Officer/Director or Control Person	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Note
Larry McLachlin	President	Blue Mountains, Ontario, Canada	0	N/A	N/A	Shares Not Yet Issued
Micro MedTech/ Windell Abraham See Note 1	Owner of more than 5%	Pohnpei, Micronesia	40,000,000	Common	24.8%	Windell Abraham, Pohnpei, Micronesia
Fit For A King/ Gerald Pettie	Owner of more than 5%	Richmond Hill, Ontario, Canada	30,005,500	Common	18.6%	Gerald Pettie, Richmond Hill, Ontario

Note 1: These shares are subject to review and cancellation for contract reasons.

## 8) Legal/Disciplinary History

A. Please identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

NO

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

NO

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding, or judgment has not been reversed, suspended, or vacated; or

NO

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

NO

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

NOT APPLICABLE

## 9) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

### Securities Counsel

Name: VIC DEVLAE MINCK  
Firm: ATTORNEY - CPA  
Address 1: 100013 N.E.HAZEL DELL AVENUE, SUITE 317  
Address 2: VANCOUVER, WASHINGTON, 98685  
Phone: (503) 806-3533  
Email: VIC@VICDEVLAE MINCK.COM

### Accountant or Auditor

Name: INTERNAL  
Firm:  
Website:  
Phone:  
Email:

### Investor Relations

Name: LARRY McLACHLIN, PRESIDENT  
Firm: HEALTH ADVANCE INC.  
Address 1: 9131 KEELE STREET, SUITE A4  
Phone: (705) 733-7098  
Email: PRESIDENT@HEALTHADVANCEGROUP.COM

### Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s) or consultant(s) or provided assistance or services to the issuer during the reporting period.

NOT APPLICABLE

## 10) Issuer Certification

*Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

I, Larry McLachlin certify that:

1. I have reviewed this [Annual Disclosure Statement](#) of [Health Advance Inc;](#)
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

June 29, 2022

/s/ LARRY McLACHLIN

President and Director

# Health Advance Inc.

## Balance Sheet As of March 31, 2022 (Unaudited)

	TOTAL	
	AS OF MAR. 31, 2022	AS OF MAR. 31, 2021 (PP)
<b>Assets</b>		
Current Assets		
Cash and Cash Equivalent		
Commercial Business Account CAN	158.81	
Commercial Business Account USD	69.94	
HADV Cash on Hand	1,282.15	1,282.15
HADV Ledger Trust Account	87.41	1,367.48
<b>Total Cash and Cash Equivalent</b>	<b>\$1,598.31</b>	<b>\$2,649.63</b>
Accounts Receivable (A/R)		
Accounts Receivable (A/R) - CAD Accounts	6,225.99	
Accounts Receivable (A/R) - US Accounts	30,000.00	30,000.00
<b>Total Accounts Receivable (A/R)</b>	<b>\$36,225.99</b>	<b>\$30,000.00</b>
Loan to Courtship Wines (CDN Funds)	87,689.16	
Loan to Courtship Wines (USD Funds)	1,700.00	
<b>Total Current Assets</b>	<b>\$127,213.46</b>	<b>\$32,649.63</b>
Non-current Assets		
Property, plant and equipment		
Furniture and Fixtures		
Computer, Printer	899.25	899.25
Office Furniture	749.37	749.37
<b>Total Furniture and Fixtures</b>	<b>1,648.62</b>	<b>1,648.62</b>
<b>Total Property, plant and equipment</b>	<b>\$1,648.62</b>	<b>\$1,648.62</b>
Intellectual Property	180,000.00	180,000.00
<b>Total Non Current Assets</b>	<b>\$181,648.62</b>	<b>\$181,648.62</b>
<b>Total Assets</b>	<b>\$308,862.08</b>	<b>\$214,298.25</b>
<b>Liabilities and Equity</b>		
Liabilities		
Current Liabilities		
Accounts Payable (A/P)		
Accounts Payable (A/P) - CAD Suppliers (USD)	19,050.02	11,811.00
Accounts Payable (A/P) - US Suppliers (USD)	22,170.55	3,021.75
<b>Total Accounts Payable (A/P)</b>	<b>\$41,220.57</b>	<b>\$14,832.75</b>
Accrued Liabilities	2,500.00	2,500.00
Loan (Short Term) from new JV Partner	3,123.16	
<b>Total Current Liabilities</b>	<b>\$46,843.73</b>	<b>\$17,332.75</b>
Non-current Liabilities		
Loan from Fit-For-A-King Inc.	43,191.17	39,613.81
Promissory Notes CDN	82,135.43	
Promissory Notes USD	110,000.00	
<b>Total Non-current Liabilities</b>	<b>\$235,326.60</b>	<b>\$39,613.81</b>
<b>Total Liabilities</b>	<b>\$282,170.33</b>	<b>\$56,946.56</b>



# Health Advance Inc.

## Balance Sheet

As of March 31, 2022

(Unaudited)

	TOTAL	
	AS OF MAR. 31, 2022	AS OF MAR. 31, 2021 (PP)
Equity		
Accumulated Deficit	-437,495.00	-437,495.00
Additional Paid-In Capital	186,080.00	186,080.00
Common Stock	303,062.00	303,062.00
Common Stock to be Issued	67,500.00	67,500.00
Retained Earnings	38,204.69	21,256.92
Profit for the year	-130,659.94	16,947.77
<b>Total Equity</b>	<b>\$26,691.75</b>	<b>\$157,351.69</b>
<b>Total Liabilities and Equity</b>	<b>\$308,862.08</b>	<b>\$214,298.25</b>

# Health Advance Inc.

## Profit and Loss April 2021 - March 2022 (Unaudited)

	TOTAL	
	APR. 2021 - MAR. 2022	APR. 2020 - MAR. 2021 (PP)
INCOME		
Joint Venture Royalty Account	6,225.99	
Sales - Product	477.55	20,000.00
<b>Total Income</b>	<b>\$6,703.54</b>	<b>\$20,000.00</b>
<b>GROSS PROFIT</b>	<b>\$6,703.54</b>	<b>\$20,000.00</b>
EXPENSES		
Bank Charges	651.51	20.82
Compliance and Transfer Agent	16,429.90	9,155.25
Consulting	29,076.17	17,382.97
Corporate Advertising / Promotion	1,984.71	
Executive Compensation	13,189.37	10,372.47
Investor Relations	4,083.80	
IT Expenses	228.56	16.50
Meals and entertainment	82.35	
Occupancy	778.99	481.75
Office Administration and Bookkeeping	20,253.10	4,139.00
Mailing, Postage	80.93	
<b>Total Office Administration and Bookkeeping</b>	<b>20,334.03</b>	<b>4,139.00</b>
Professional Fees		300.00
Legal	45,622.72	
<b>Total Professional Fees</b>	<b>45,622.72</b>	<b>300.00</b>
Sales Tax Paid	194.49	85.45
Shipping Charges	12.32	
Supply - Test Kits	458.04	
Telephone Charges	157.35	
Travel and Fuel Expenses	393.39	
<b>Total Expenses</b>	<b>\$133,677.70</b>	<b>\$41,954.21</b>
OTHER INCOME		
Recoveries		38,902.00
<b>Total Other Income</b>	<b>\$0.00</b>	<b>\$38,902.00</b>
OTHER EXPENSES		
Exchange Gain or Loss	3,685.78	0.02
<b>Total Other Expenses</b>	<b>\$3,685.78</b>	<b>\$0.02</b>
<b>PROFIT</b>	<b>\$ -130,659.94</b>	<b>\$16,947.77</b>

# Health Advance Inc.

## Statement of Cash Flows

April 2021 - March 2022

(Unaudited)

	TOTAL
OPERATING ACTIVITIES	
Net Income	-130,659.94
Adjustments to reconcile Net Income to Net Cash provided by operations:	
Accounts Receivable (A/R) - CAD Accounts	-6,225.99
Loan to Courtship Wines (CDN Funds)	-87,689.16
Loan to Courtship Wines (USD Funds)	-1,700.00
Accounts Payable (A/P) - CAD Suppliers (USD)	7,239.02
Accounts Payable (A/P) - US Suppliers (USD)	19,148.80
Loan (Short Term) from new JV Partner	3,123.16
<b>Total Adjustments to reconcile Net Income to Net Cash provided by operations:</b>	<b>-66,104.17</b>
<b>Net cash provided by operating activities</b>	<b>\$ -196,764.11</b>
FINANCING ACTIVITIES	
Loan from Fit-For-A-King Inc.	3,577.36
Promissory Notes CDN	82,135.43
Promissory Notes USD	110,000.00
<b>Net cash provided by financing activities</b>	<b>\$195,712.79</b>
<b>NET CASH INCREASE FOR PERIOD</b>	<b>\$ -1,051.32</b>
Cash at beginning of period	2,649.63
<b>CASH AT END OF PERIOD</b>	<b>\$1,598.31</b>

**Health Advance Inc.**  
**Statement of Changes in Stockholder's Equity**  
**for the Year Ending March 31, 2022**  
(Unaudited)

	<u>Common Stock Shares</u>	<u>Stock Amount</u>	<u>Paid-in Capital</u>	<u>Accum. Def. Retained Earnings</u>	<u>Total Shareholders' Equity</u>
Bal Mar 31/19	158,027,500	341,362	186,080	(437,895)	118,747
Issued Jun 25/19	520,000	5,200			5,200
Issued Jun 25/19	2,400,000	24,000			24,000
Issued Dec 11/19	160,000,000 *	0			0
Income Mar 31/20				21,656	21,656
Mar 31/20	320,947,500	370,562	186,080	(416,238)	140,403
Cancelled Feb 22/21 (160,000,000) *		0			0
Income Mar 31/21				16,948	16,948
March 31, 2021	160,947,500	370,562	186,080	(399,290)	157,351
Income (Loss)					
March 31, 2022				(130,659)	
March 31, 2022	160,947,500	370,562	186,080	(529,949)	26,693

\*

## **NOTES TO THE FINANCIAL STATEMENTS OF HEALTH ADVANCE INC FOR THE FISCAL YEAR ENDING MARCH 31, 2022**

### **1. NATURE OF OPERATIONS AND ORGANIZATION**

Health Advance Inc. (the “Company” or “Health Advance”) was incorporated on April 14, 2010 in the State of Wyoming. The Company was originally a development stage online retailer of home medical products with operations in Canada and the United States. Since that time, the Company has pursued broader business opportunities in the field of human wellness. The Company is in good standing with the State of Wyoming.

### **2. BASIS OF PRESENTATION**

The condensed financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the USA for the Alternative Reporting Guidelines of OTC Markets. All adjustments, consisting of normal recurring accruals, considered necessary for a fair presentation have been included.

### **3. GOING CONCERN**

These financial statements have been prepared assuming the Company will continue on a going concern basis. The Company has incurred losses, historically, and the ability of the Company to continue as a going concern depends upon its ability to develop profitable operations and to continue to raise adequate financing. Management is actively seeking sources of additional financing to provide continuation of the Company's operations. In order for the Company to meet its liabilities as they come due and to continue its operations, the Company is solely dependent upon its ability to generate such financing.

There can be no assurance that the Company will be able to continue to raise funds, in which case the Company may be unable to meet its obligations. Should the Company be unable to realize its assets and discharge its liabilities in the normal course of business, the net realizable value of its assets may be materially less than the amounts recorded in these financial statements. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

### **4. PROFIT / LOSS PER SHARE**

The Company has not yet adopted the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") Topic 260-10 which provides for calculation of “basic” and “diluted” earnings per share. Basic earnings per share includes no dilution and is computed by dividing net income or loss available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. Diluted earnings per share exclude all potentially dilutive shares if their effect is anti-dilutive.

## 5. ACCOUNTING PRONOUNCEMENTS

### Periodically Issued Accounting Standards

The Company has not yet adopted all accounting pronouncements issued by the Financial Accounting Standards Board ("FASB") that would apply to SEC reporting issuers, which Health Advance is not. For illustration only, the guidance on how companies account for certain aspects of share-based payments to employees, This pronouncement, for illustration, became effective for fiscal years beginning after December 15, 2016. This guidance called for income tax effects of awards to be recognized in the income statement when the awards vest or are settled and changes the presentation of excess tax benefits on the statement of cash flows. In addition, this pronouncement changes guidance on: (a) accounting for forfeitures of share-based awards and (b) employers' accounting for an employee's use of shares to satisfy the employer's statutory income tax withholding obligation. In the opinion of management adoption of this pronouncement in particular, and similar pronouncements in general, would not have a material impact on Company's financial position and/or results of operations until such time that the scale of the Company's operation expands considerably. The cost and complexity of applying such measures are not feasible, or material, for the Company at the present time. Readers are therefore cautioned that these unaudited internal financial statements may not be suitable for their purposes, notwithstanding the attempt within these statements to present fairly the material conditions of the Company.

## 6. RELATED PARTY TRANSACTIONS AND BALANCES

The transactions with any related parties are kept within standards that would apply to arm's length transactions unless otherwise specified in the Company's disclosures.

## 7. CONTINUITY

The financial statements of Health Advance were audited up to and including the 2016 fiscal year. Former management undertook to vend in business projects that would have required international auditing that exceeded the company's financial resources relative to the potential value of the vend in. They did not therefore carry on with auditing. The current information disclosure filed with OTC Markets under the Alternative Reporting Guidelines resets to the present from the last audited trial balance, rather than from the unaudited EDGAR Q filings, and does not merge largely non-cash subsequent activity in the interests of present clarity and reality. Only known assets are recorded. Liabilities which are statute-barred or forgiven are reflected as recoveries. This serves the cause of accuracy of the current information by avoiding all unsubstantiated presumptions, and restoring simple, reliable and up-to-date presentation of the present conditions. Management believes that no taxes are payable due to the historical absence of net profit and substantial tax loss carry-forwards. The Company may amend any aspect of the financial statements and other disclosure if new information calls for restatement of any fact.



Secretary of State

## DETAIL



[RETURN TO YOUR SEARCH](#)



[FILE YOUR ANNUAL REPORT](#)

### Health Advance Inc.

This detail reflects the current data for the filing in the system.

[Print](#)

**Name**

Health Advance Inc.

**Filing ID**

2010-000583118

**Type**

Profit Corporation - Domestic

**Status**

Active

**Sub Status**

Current

**Initial Filing**

04/14/2010

**Standing - Tax**

Good

**Standing - RA**

Good

**Standing - Other**

Good

**Term of Duration**

Perpetual

**Formed In**

Wyoming

**Fictitious Name****Principal Office**

Suite A4 - 9131 Keele St  
Vaughan, Ontario L4K 0G7  
Canada

**Mailing Address**

Suite A4 - 9131 Keele St  
Vaughan, Ontario L4K 0G7  
Canada